Last reviewed · How we verify
Capecitabine in Combination with Cisplatin and Irinotecan
Capecitabine in Combination with Cisplatin and Irinotecan is a Small molecule drug developed by University of New Mexico. It is currently in Phase 1 development.
At a glance
| Generic name | Capecitabine in Combination with Cisplatin and Irinotecan |
|---|---|
| Sponsor | University of New Mexico |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Hypokalaemia
- Anaemia
- Respiratory tract infection
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Thyroid function test abnormal
- Hypocalcaemia
- Hypoproteinaemia
- Proteinuria
- Hypertension
- Leukopenia
Key clinical trials
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors (PHASE2)
- Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors (PHASE1)
- Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors (PHASE1)
- A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors (PHASE1, PHASE2)
- A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. (PHASE1)
- Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine in Combination with Cisplatin and Irinotecan CI brief — competitive landscape report
- Capecitabine in Combination with Cisplatin and Irinotecan updates RSS · CI watch RSS
- University of New Mexico portfolio CI
Frequently asked questions about Capecitabine in Combination with Cisplatin and Irinotecan
What is Capecitabine in Combination with Cisplatin and Irinotecan?
Capecitabine in Combination with Cisplatin and Irinotecan is a Small molecule drug developed by University of New Mexico.
Who makes Capecitabine in Combination with Cisplatin and Irinotecan?
Capecitabine in Combination with Cisplatin and Irinotecan is developed by University of New Mexico (see full University of New Mexico pipeline at /company/university-of-new-mexico).
What development phase is Capecitabine in Combination with Cisplatin and Irinotecan in?
Capecitabine in Combination with Cisplatin and Irinotecan is in Phase 1.
What are the side effects of Capecitabine in Combination with Cisplatin and Irinotecan?
Common side effects of Capecitabine in Combination with Cisplatin and Irinotecan include Upper respiratory tract infection, Hypokalaemia, Anaemia, Respiratory tract infection, Alanine aminotransferase increased, Aspartate aminotransferase increased.